Holen Sie sich die Stockscreener-App
4.85
3.63%
0.17
Handel nachbörslich:
4.85
Larimar Therapeutics Inc Aktie (LRMR) Neueste Nachrichten
Larimar reports results, advances Nomlabofusp toward FDA filing - MSN
Larimar Reports Results, Advances Nomlabofusp Toward FDA Filing - MyChesCo
RSI Check: Will Larimar Therapeutics Inc benefit from geopolitical trendsWeekly Trading Summary & Consistent Growth Stock Picks - baoquankhu1.vn
Larimar heads to JPMorgan as rare disease program draws investor attention - MSN
Larimar Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Larimar surges on FDA breakthrough status for lead asset - MSN
Larimar Therapeutics (LRMR) Expected to Announce Earnings on Monday - MarketBeat
Institution Moves: Is Larimar Therapeutics Inc impacted by rising ratesTrade Exit Report & Low Risk Entry Point Tips - baoquankhu1.vn
Larimar Therapeutics (NASDAQ:LRMR) Stock Price Up 8.2% After Analyst Upgrade - MarketBeat
Wedbush Increases Larimar Therapeutics (NASDAQ:LRMR) Price Target to $13.00 - MarketBeat
LRMR Stock: Wedbush Raises Price Target to $13, Maintains Outper - GuruFocus
Larimar Therapeutics (LRMR) Q4 EPS Misses Estimates - GuruFocus
Larimar Therapeutics stock rating reiterated by William Blair - Investing.com Canada
Nomlabofusp push at Larimar Therapeutics (NASDAQ: LRMR) targets 2026 BLA - Stock Titan
Larimar Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Larimar Therapeutics reports Q4 EPS (73c), consensus (55c) - TipRanks
FDA grants breakthrough status to Larimar’s nomlabofusp - MSN
Larimar (LRMR) Poised for Milestone Achievements and Financial S - GuruFocus
Larimar Therapeutics, Inc. has established a clear regulatory approval and commercialization timeline for its core candidate product. - Bitget
Larimar: Q4 Earnings Snapshot - KTVB
Larimar Therapeutics Receives Breakthrough Therapy Designation for Nomlabofusp in Friedreich's Ataxia, Plans BLA Submission for June 2026 - Quiver Quantitative
LRMR: Nomlabofusp advances toward BLA submission with strong cash position and FDA alignment - TradingView
Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Larimar Therapeutics Q4 net loss widens on higher R&D costs - TradingView
Larimar (NASDAQ: LRMR) secures FDA Breakthrough status and funds runway to 2027 - Stock Titan
BRIEF-Larimar Therapeutics Q4 Net Income USD -62.498 Million - TradingView
FDA grants Breakthrough status to rare disease drug as June filing nears - Stock Titan
IPO Launch: Does Larimar Therapeutics Inc have consistent dividend growth2026 Summary & Risk Managed Trade Strategies - baoquankhu1.vn
Should I invest in Larimar Therapeutics Inc before earningsSwing Trade & Growth Focused Investment Plans - baoquankhu1.vn
Larimar Therapeutics Reports Q1 2025 Results and Advances Nomlabofusp Development - MSN
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Sees Significant Decrease in Short Interest - MarketBeat
Aug Gainers: How volatile is Larimar Therapeutics Inc stockTrade Exit Summary & AI Based Trade Execution Alerts - baoquankhu1.vn
Mangrove Partners IM LLC Sells 327,997 Shares of Larimar Therapeutics, Inc. $LRMR - MarketBeat
Investors Purchase Large Volume of Larimar Therapeutics Call Options (NASDAQ:LRMR) - MarketBeat
Larimar Therapeutics (NASDAQ:LRMR) Stock Price Down 8%Should You Sell? - MarketBeat
Larimar Advances Nomlabofusp Toward 2026 BLA Submission - The Globe and Mail
LRMR: Nomlabofusp shows strong efficacy and regulatory momentum for Friedreich's ataxia, with BLA submission planned for 2026 - TradingView
Larimar Therapeutics posts updated corporate deck outlining nomlabofusp BLA plan, Q2 2026 topline and cash runway - TradingView
Larimar Therapeutics (LRMR) advances nomlabofusp toward 2026 BLA and Phase 3 - Stock Titan
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Larimar Therapeutics stock dips after pricing $100M share offering - MSN
Blue Owl Capital Holdings LP Has $18.91 Million Stock Holdings in Larimar Therapeutics, Inc. $LRMR - MarketBeat
ETF Watch: Is Larimar Therapeutics Inc. stock a good choice for value investorsMarket Movers & Verified Swing Trading Watchlists - Naître et grandir
LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month? - TradingView
Larimar Therapeutics to Participate in Upcoming Investor Conferences in March - Sahm
Larimar Therapeutics Launches $75 Million Public Offering of Common Stock and Pre-Funded Warrants - Global Legal Chronicle
Larimar Therapeutics price target raised to $12 from $11 at Wedbush - finance.yahoo.com
FDA Grants Breakthrough Status to Larimar’s Nomlabofusp - MyChesCo
Wedbush Maintains Outperform on Larimar Therapeutics, Inc. (LRMR) March 2026 - Meyka
LRMR Stock Rating Maintained Outperform by Wedbush, Price Target - GuruFocus
Wedbush raises Larimar Therapeutics stock price target to $12 By Investing.com - Investing.com Canada
Wedbush raises Larimar Therapeutics stock price target to $12 - Investing.com
Larimar Therapeutics (NASDAQ:LRMR) Price Target Raised to $12.00 - MarketBeat
Larimar Therapeutics Stock (LRMR) Opinions on Public Offering and Insider Purchases - Quiver Quantitative
0.04%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):